|
Dabigatran has higher bleeding risk than warfarin in dialysis patients |
 |
|
Healio.com (Circulation): "Our study is the first to evaluate these drugs in the dialysis population, and suggests concern given the increasing use of dabigatran and rivaroxaban in the ESRD population despite formal FDA warnings of caution in renal failure," the researchers wrote. "In fact, our secondary analyses suggest excess morbidity and mortality from bleeding are associatively higher with dabigatran and rivaroxaban when compared to warfarin."
|